management of the primary in stage iv colorectal cancer · management of the primary in stage iv...
TRANSCRIPT
Management of the primary in Stage IV colorectal cancer
Erin Kennedy, MD, PhD, FRCSC
Colorectal Surgery
Mount Sinai Hospital
University of Toronto
Stage IV Colorectal Cancer
• 15%-20% CRC patients present with Stage IV disease
• Treatment decision making challenging– Liver mets
– Colon/Rectal Primary
– Optimal timing and sequence of interventions
• Treatment strategy influenced by:– potential resectability of the liver
– symptom pattern of the primary
Assessment of the liver: Resectable, borderline or unresectable
• Accurate assessment of the liver is essential:
– intent of treatment (curative vs palliative)
– timing and sequence of treatment
• Many modalities to treat liver metastases– Surgery +/- PVE
– Chemotherapy
– Radiofrequency ablation (RFA)
– Intra-arterial chemotherapy
Assessment of the liver: Resectable, borderline or unresectable
• Synchronous mets, multiple mets and bilobar disease no longer contraindications to resection
• Assessment of liver mets by HPB surgeon necessary
– Resectable - Curative
– Borderline - Possibly curative
– Unresectable - Palliative
Current Approaches to the Liver
• Traditional - primary followed by liver
• Simultaneous - primary and liver together
– 5 year survival ~30-40%
• “Liver first approach”1. Pre-operative chemotherapy
2. Liver
3. Primary
– Patient outcome related to progression of liver mets– Avoids delay in treatment of liver metastasis from:
– Complications from colorectal surgery
– Long course chemoradiation for rectal cancer
– Minimal data available
Assessment of the Primary Symptomatic or Asymptomatic?
• Symptomatic– Perforation
– Bleeding - transfusion dependent
– Obstruction requiring admission or “impending obstruction”
– Scope does not pass through tumour
– Proximal bowel dilatation on imaging
• Asymptomatic– Most not truly asymptomatic
• Bottom line is that it is often a judgement call
Definitely resectable
Liver - Definitely Resectable – Curative Intent
Symptomatic Asymptomatic
Traditional approach Traditional approach(Liver first approach)
CONSIDERATIONS:•Low threshold for protective stoma (avoid complications)•Simultaneous resection in select cases•Short course radiation for rectal cancer
Borderline (potentially resectable)
Liver – Borderline - Potentially curable
Symptomatic Asymptomatic
Need chemotherapy ASAPSurgery to:•minimize complications•promote fast recoveryColonR side - resectL side – resect + divertRectumDiversion only
Liver first approach(Traditional approach)
“Liver First Approach” for patients with locally advanced Stage IV rectal cancer
• 23 consecutive patients, 2003-2007
• Synchronous liver mets – locally advanced rectal cancer (T3-T4)
• Single centre, prospective study1. Neoadjuvant chemotherapy
• 5FU + (oxaliplatin or irinotecan) +/- avastin X 2-3 cycles
2. Liver resection (3 weeks after chemo; 6 weeks if avastin)
3. Chemoradiation for primary tumour
4. TME
Verhoef, Diseases of the Colon and Rectum 2009;52:23-30
Median age, yrs 58 (43-78)SexMale Female
158
PresentationObstructionPainBlood loss/bowel habit
6116
Number of mets< 3>3
149
Size of mets< 5 cm> 5 cm
203
Bilobar diseaseYesNo
1211
CEA< 5> 5
518
“Liver First Approach” for patients with locally advanced Stage IV rectal cancer
• 15 patients – partial response
• 6 patients – stable disease
• 1 patient – complete remission (liver and primary)
• Sx from primary improved after initiation of chemotherapy
– 1 patient required diverting colostomy for obstruction
Verhoef, Diseases of the Colon and Rectum 2009;52:23-30
“Liver First Approach” for patients with locally advanced Stage IV rectal cancer
• Median follow up 18 months (7-56)
• 16 patients completed treatment
– 14 NED (7-56 months)
– 2 alive with pulmonary mets (20 and 29 months)
• ~60% potentially curative treatment
Verhoef, Diseases of the Colon and Rectum 2009;52:23-30
Both stages completed
Median follow up, months
Median OS, months
Recurrence rate, n (%)
3 yr OS (%)
Mentha, 2008 30/35 (86) NR 44 20/30 (68) 60
Verhoef, 2009 16/23 (70) 18 19 2/16 (13) 89
Brouquet, 2010 27/41 (66) 25 50 19/27 (70) 79
DeJong, 2011
18/22 (73) NR 36 6/18 (33) 41
TOTAL 91/121 (75) 47/91 (52)
V Lam et al. A systematic review of a liver first approach in patients with colorectal cancer and synchronous colorectal liver metastasis. HPB 2014;16:101-108
Definitely unresectable
Liver – Definitely Unresectable – Palliative
Symptomatic* AsymptomaticNeed chemotherapy ASAP Surgery for primary:Minimize complicationsPromote fast recovery ColonR side – resectionL side – more likely to divert Rectum – diversion onlyPalliative radiation if continued symptoms
Chemotherapy Surgery only if complications develop (10%)
*If < 3 months life expectancy – avoid surgery
Outcome of primary tumour in patients receiving chemotherapy without surgery
Poultsides GA. JCO 2009;27(20):3379-3384
• Retrospective study using prospectively maintained database
• 233 consecutive patients 200-2006
• Synchronous metastatic CRC with intact primary
• Received chemotherapy
• Complications of primary tumour– Surgery, radiotherapy and/or endoluminal stenting
Median age, yrs 60 (28-86)Primary tumourRight colonLeft colonRectum
37% (87)29% (68)34% (78)
Site of metastasisLiverLung Retroperitoneal nodes
95% (221)30% (70)39% (91)
Number of sites of mets1234
40% (94)45% (106)12% (29)
2% (4)
First Line ChemotherapyFOLFOXFOLFIRIAvastin
60% (139)40% (94)48% (112)
Risk of emergent intervention not associated with age, location of primary, number of metastatic sites, avastin or CEA
Median overall survival – 18 months
Summary
• All patients with Stage IV disease need HPB assessment to assess “resectability”
• “Liver first” approach may be most uselful in setting of borderline resectability of liver mets
• First line chemotherapy for unresectable CRC mets AND asymptomatic primary is effective and safe
• No high quality evidence to guide treatment
• Need to individualize treatment based on:– Tumour and patient factors
– Patient preference
– MCC